Home » Newsletters » BioWorld Science

BioWorld Science

July 23, 2002

View Archived Issues

Altair develops new drug for hyperphosphatemia in hemodialysis patients

Dose-ranging stage of Surfaxin phase II trial completed

Immune Network and ViroLogic enter hNM01 research collaboration in HIV

Progress of Ranbaxy compounds in second quarter

Biogen updates advances in late-stage pipeline

Topiramate may be useful for managing behavioral disturbances associated with AD

New cognition-enhancing agents developed at Zenyaku Kogyo

NCX-4016 protects endothelium and kidney function in diabetic rats via NO release

Muscarinic M1 agonists: do they or do they not improve cognitive function?

Neurotensin antagonist shows potential for preventing relapse in cocaine addicts

Potent and selective NK3 receptor antagonist characterized biochemically and pharmacologically

Novel tachykinin NK2/NK3 antagonists claimed by GSK

New antithrombin agents designed by AstraZeneca scientists

Orexin antagonists and their use in obesity and other disorders discussed in recent patent

Karo Bio presents liver-selective glucocorticoid antagonists

Novel 5-HT1A antagonists in early development at Wyeth

AstraZeneca patent describes MEK inhibitors for use in cancer

Inhibitors of ICAM/leukointegrin interaction identified at BMS and Cerep

Roche Bioscience identifies series with potent and selective CCR3-antagonist profile

First Cyclis program set to enter phase I in mid-2003

Ragaglitazar development suspended

Aranesp approved for chemotherapy-induced anemia

Zonagen awarded SBIR grant for Progenta

S-1360 well tolerated in phase I

HE-2200 increases survival in preclinical model of lupus

Nasonex indication expanded to include children as young as two years

Iloperidone completes EKG study

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026